Featuring a slide presentation and related discussion from Dr Lindsey Roeker, including the following topics:
- Recent clinical updates with standard regimens for chronic lymphocytic leukemia (CLL) (0:00)
- Utility of minimal residual disease-guided treatment intensification after ibrutinib with venetoclax (7:03)
- Major long-term findings from the GLOW study of ibrutinib with venetoclax (10:35)
- Principal findings from the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab (12:28)
- Findings with combined acalabrutinib, venetoclax and obinutuzumab for patients with previously untreated high-risk disease (15:52)
- Early clinical findings with sonrotoclax and zanubrutinib as front-line treatment for CLL (18:12)
- Principal findings from the BRUIN CLL-321 trial of pirtobrutinib for patients who previously received a covalent Bruton tyrosine kinase (BTK) inhibitor (19:38)
- Emerging evidence with pirtobrutinib, venetoclax and obinutuzumab as front-line treatment (22:15)
- Novel strategy combining lisocabtagene maraleucel with ibrutinib for relapsed/refractory (R/R) CLL (24:13)
- Available data with epcoritamab monotherapy for R/R CLL (26:58)
- The emerging pharmacologic class of BTK degraders (29:04)
CME information and select publications
View all episodes
